Leal Health Launches Predictive Patient Journey Solution
New technology aims to streamline cancer treatment process.
Leal Health, formerly known as Trialjectory, an AI-powered platform for patient access to advanced cancer treatments, has launched a predictive patient tool designed to help cancer patients navigate their treatment journey at all stages of the disease. Its aim is to educate patients and their oncologists on their treatment options in a timely manner and to remove barriers to care in advance. The goal as well is to enable pharmaceutical companies to better identify potential patients that could match to their trials in the future.
With this technology, Leal’s platform, according to the company, can preemptively match cancer patients with available treatment options that could be relevant for them in the future should their disease progress. At the same time, Leal provides pharma companies and clinical trial sponsors insight into patients who have a high probability of participating in future trials due to their disease state. For example, sponsors can access insight into how minority and underrepresented patients’ cancer changes over time and how patients can adjust current treatments to remain eligible for other clinical trials.
“For most patients, cancer isn’t a one-and-done fight; it’s an ongoing, ever-changing war. Because cancer states change over time, a treatment that might not be relevant for a patient today could become a game changer down the line,” says Tzvia Bader, Co-founder and CEO, Leal Health. “With this offering, patients who fail a treatment can quickly pivot to a new therapy identified by Leal that is appropriate for them, rather than having to start a new search from scratch and waste valuable time that they may not have.”
Reference: Leal Health Launches Industry-First Predictive Patient Journey Offering, NEW YORK, N.Y., May 8, 2023.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
